The bankruptcy underscores the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations.

Me’s genetic data may be for sale after bankruptcy. AI firms may want in—but privacy fears could make it a toxic asset.

Me on Sunday filed for bankruptcy in the U.S. after struggling with weak demand for its ancestry testing kits and a 2023 data ...

23andme says it owns the aggregated genetic data of its customers, meaning it can sell it to the highest bidder ...

But since 23andMe is not a medical provider it does not have to abide by standard privacy policies that must be followed at a doctor's office. Such services are "not regulated well," said Ayday.

DNA testing pioneer 23andMe filed ... would love to see a space where people can get the information they want without feeling as though that information might put them at risk,” Cohen said.

Once portrayed as a pioneer in consumer genetics, 23andMe (ME) filed for Chapter 11 bankruptcy on Sunday, leaving behind a trail of angry ...

Just before the 23andMe SPAC deal closed, the stock belonging to ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets ...

Just before the 23andMe SPAC deal closed, the stock belonging to ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets ...

23andMe bankruptcy underscores the risk of investing in most SPACs ... whose mission is to make acquisitions. Then the SPAC converts its ticker symbol and name over to one matching the name ...